Significant cross talk between aberrant MET pathway and other signaling pathways, especially EGFR results in acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in patients with NSCLC [19]. Here, MET is linked to non-small cell lung carcinoma.